The 36-month beta value for ZVRA is at 1.85. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZVRA is 39.94M, and currently, shorts hold a 5.63% of that float. The average trading volume for ZVRA on April 11, 2024 was 245.40K shares.
ZVRA) stock’s latest price update
Zevra Therapeutics Inc (NASDAQ: ZVRA)’s stock price has gone rise by 4.02 in comparison to its previous close of 4.73, however, the company has experienced a -2.19% decrease in its stock price over the last five trading days. Seeking Alpha reported 2024-03-28 that Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
ZVRA’s Market Performance
ZVRA’s stock has fallen by -2.19% in the past week, with a monthly drop of -19.74% and a quarterly drop of -20.45%. The volatility ratio for the week is 5.66% while the volatility levels for the last 30 days are 5.01% for Zevra Therapeutics Inc The simple moving average for the past 20 days is -12.16% for ZVRA’s stock, with a -6.24% simple moving average for the past 200 days.
Analysts’ Opinion of ZVRA
Many brokerage firms have already submitted their reports for ZVRA stocks, with Maxim Group repeating the rating for ZVRA by listing it as a “Buy.” The predicted price for ZVRA in the upcoming period, according to Maxim Group is $18 based on the research report published on April 02, 2024 of the current year 2024.
Maxim Group gave a rating of “Buy” to ZVRA, setting the target price at $12 in the report published on March 17th of the previous year.
ZVRA Trading at -18.36% from the 50-Day Moving Average
After a stumble in the market that brought ZVRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.42% of loss for the given period.
Volatility was left at 5.01%, however, over the last 30 days, the volatility rate increased by 5.66%, as shares sank -21.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.26% lower at present.
During the last 5 trading sessions, ZVRA fell by -2.19%, which changed the moving average for the period of 200-days by -11.03% in comparison to the 20-day moving average, which settled at $5.54. In addition, Zevra Therapeutics Inc saw -24.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZVRA starting from Anderson Thomas, who purchase 10,000 shares at the price of $4.88 back on Sep 06 ’23. After this action, Anderson Thomas now owns 10,000 shares of Zevra Therapeutics Inc, valued at $48,764 using the latest closing price.
Clifton R. LaDuane, the CFO, Secretary & Treasurer of Zevra Therapeutics Inc, purchase 1,000 shares at $4.96 during a trade that took place back on Sep 06 ’23, which means that Clifton R. LaDuane is holding 15,309 shares at $4,959 based on the most recent closing price.
Stock Fundamentals for ZVRA
Current profitability levels for the company are sitting at:
- -1.81 for the present operating margin
- 0.86 for the gross margin
The net margin for Zevra Therapeutics Inc stands at -1.68. The total capital return value is set at -0.5. Equity return is now at value -62.37, with -31.99 for asset returns.
Based on Zevra Therapeutics Inc (ZVRA), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -0.77. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -33.05.
Currently, EBITDA for the company is -48.6 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 7.81. The receivables turnover for the company is 1.58for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In conclusion, Zevra Therapeutics Inc (ZVRA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
